Open access

Dedicated anticoagulation management protocols in fragility femoral fracture care - a source of significant variance and limited effectiveness in improving time to surgery: The hip and femoral fracture anticoagulation surgical timing evaluation (HASTE) study

Posted on by

Type of publication:
Journal article

Author(s):
Farhan-Alanie M.M.; Dixon J.; Irvine S.; Walker R.; Eardley W.G.P.; Smith M.; Yoong A.; Lim J.W.; Yousef O.; McDonald S.; Chileshe C.; Ramus C.; Clements C.; Barrett L.; Rockall O.; Geetala R.; Islam S.U.; Nasar A.; Almond K.; Hassan L.F.Y.; Brand R.B.; Yawar B.; Gilmore C.; McAuley D.; Khan W.; Subramanian P.; Ahluwalia A.; Ozbek L.; Awasthi P.; Sheikh H.; Barkley S.; Ardolino T.; Denning A.; Thiruchandran G.; Fraig H.; Salim O.; Iqbal R.; Guy S.; Hogg J.; Bagshaw O.; Asmar S.; Mitchell S.; Quek F.; Fletcher J.; French J.; Graham S.; Sloper P.; Sadique H.; Matera V.; Sohail Z.; Leong J.W.; Issa F.; Greasley L.; Marsden S.; Parry L.; Mannan S.; Zaheen H.; Moriarty P.; Manning W.; Morris T.; Brockbanks C.; Ward P.; Pearce K.; McMenemy L.; Mahmoud M.; Kieffer W.; Lal A.; Collis J.; Chandrasekaran K.; Foxall-Smith M.; Raad M.; Kempshall P.; Cheuk J.; Leckey S.; Gupta R.; Engelke D.; Kemp M.; Venkatesan A.; Hussain A.; Simons M.; Raghavendra R.M.; Rohra S.; Deo S.; Vasarhelyi F.; Thelwall C.; Cullen K.; Al-Obaidi B.; Fell A.; Thaumeen A.; Dadabhoy M.; Ali M.; Ijaz S.; Lin D.; Khan B.; Alsonbaty M.; Lebe M.; Millan R.K.; Imam S.; Theobald E.; Cormack J.; Sharoff L.; Eardley W.; Jeyapalan R.; Alcock L.; Clayton J.; Bates N.; Mahmoud Y.; Osborne A.; Ralhan S.; Carpenter C.; Ahmad M.; Ravi S.M.; Konbaz T.; Lloyd T.; Sheikh N.; Swealem A.; Soroya E.; Rayan F.; Ward T.; Vasireddy A.; Clarke E.; Sikdar O.; Smart Y.W.; Windley J.; Ilagan B.; Brophy E.; Joseph S.; Lowery K.; Jamjoom A.; Ismayl G.; Aujla R.; Sambhwani S.; Ramasamy A.; Khalaf A.; Ponugoti N.; Teng W.H.; Masud S.; Otoibhili E.; Clarkson M.; Nafea M.; Sarhan M.; Hanna S.; Kelly A.; Curtis A.; Gourbault L.; Tarhini M.; Platt N.; Fleming T.; Pemmaraju G.; Choudri M.J.; Burahee A.; Hassan L.; Hamid L.; Loveday D.; Edres K.; Schankat K.; Granger L.; Goodbun M.; Parikh S.; Johnson-Lynn S.; Griffiths A.; Rai A.; Chandler H.; Guiot L.; Appleyard T.; Robinson K.; Fong A.; Watts A.; Stedman T.; Walton V.; Inman D.; Liaw F.; Hadfield J.; McGovern J.; Baldock T.; White J.; Seah M.; Jacob N.; Ali Z.H.; Goff T.; Sanalla A.; Gomati A.; Nordin L.; Hassan E.; Ramadan O.; Teoh K.H.; Baskaran D.; Ngwayi J.; Abbakr L.; Blackmore N.; Mansukhani S.; Guryel E.; Harper A.; Cashman E.; Brooker J.; Pack L.; Regan N.; *Wagner W.; *Selim A.; *Archer D.; *McConaghie G.; *Patel R.; *Gibson W.; Pasapula C.S.; Youssef H.; Aziz M.A.; Subhash S.; Banaszkiewicz P.; Elzawahry A.; Neo C.; Wei N.; Bhaskaran A.; Sharma A.; Factor D.; Shahin F.; Shields D.; Ferreira C.D.F.; Jeyakumar G.; Liao Q.; Sinnerton R.; Ashwood N.; Sarhan I.; Ker A.; Phelan S.; Paxton J.; McAuley J.; Moulton L.; Mohamed A.; Dias A.; Ho B.; Francis D.; Miller S.; Phillips J.; Jones R.; Arthur C.; Oag E.; Thutoetsile K.; Bell K.; Milne K.; Whitefield R.; Patel K.; Singh A.; Morris G.; Parkinson D.; Patil A.; Hamid H.; Syam K.; *Singh R.; *Menon D.; *Crooks S.; Borland S.; Rohman A.; Nicholson A.; Smith B.; Hafiz N.; Kolhe S.; Waites M.; Piper D.; Westacott D.; Grimshaw J.; Bott A.; Berry A.; Battle J.; Flannery O.; Iyengar K.P.; Thakur A.W.; Yousef M.; Bansod V.; El-nahas W.; Dawe E.; Oladeji E.; Federer S.; Trompeter A.; Pritchard A.; Shurovi B.; Jordan C.; Little M.; Sivaloganathan S.; Shaunak S.; Watters H.; Luck J.; Zbaeda M.; Frasquet-Garcia A.; Warner C.; Telford J.; Rooney J.; Attwood J.; Wilson F.; Panagiotopoulos A.; Keane C.; Scott H.; Mazel R.; Maggs J.; Skinner E.; McMunn F.; Lau J.; Ravikumar K.; Thakker D.; Gill M.; McCarthy P.; Fossey G.; Shah S.; McAlinden G.; McGoldrick P.; O'Brien S.; Patil S.; Millington A.; Umar H.; Sehdev S.; Dyer-Hill T.; Yu Kwan T.; Tanagho A.; Hagnasir A.; White T.; Bano C.; Kissin E.; Ghani R.; Thomas P.S.W.; McMullan M.; Walmsley M.; Elgendy M.; Winstanley R.; Round J.; Baxter M.; Thompson E.; Hogan K.; Youssef K.; Fetouh S.; Hopper G.P.; Simpson C.; Warren C.; Waugh D.; Nair G.; Ballantyne A.; Blacklock C.; O'Connell C.; Toland G.; McIntyre J.; Ross L.; Badge R.; Loganathan D.; Turner I.; Ball M.; Maqsood S.; Deierl K.; Beer A.; Tan A.C.W.; Mackinnon T.; Gade V.; Gill J.; Yu San K.; Archunan M.W.; Shaikh M.; Ugbah O.; Uwaoma S.; Pillai A.; Nath U.; Rohan

Citation:
Injury. 55(8) (no pagination), 2024. Article Number: 111686. Date of Publication: August 2024. [epub ahead of print]

Abstract:
Introduction: Approximately 20 % of femoral fragility fracture patients take anticoagulants, typically warfarin or Direct Oral AntiCoagulant (DOAC). These can impact timing of surgery affecting patient survival. Due to several possible approaches and numerous factors to consider in the preoperative workup of anticoagulated patients, potential for variations in clinical practice exist. Some hospitals employ dedicated anticoagulation management protocols to address this issue, and to improve time to surgery. This study aimed to determine the proportion of hospitals with such protocols, compare protocol guidance between hospitals, and evaluate the effectiveness of protocols in facilitating prompt surgery. Method(s): Data was prospectively collected through a collaborative, multicentre approach involving hospitals across the UK. Femoral fragility fracture patients aged >=60 years and admitted to hospital between 1st May to 31st July 2023 were included. Information from dedicated anticoagulation management protocols were collated on several domains relating to perioperative care including administration of reversal agents and instructions on timing of surgery as well as others. Logistic regression was used to evaluate effects of dedicated protocols on time to surgery. Result(s): Dedicated protocols for management of patients taking warfarin and DOACs were present at 41 (52.6 %) and 43 (55.1 %) hospitals respectively. For patients taking warfarin, 39/41 (95.1 %) protocols specified the dose of vitamin k and the most common was 5 milligrams intravenously (n=21). INR threshold values for proceeding to surgery varied between protocols; 1.5 (n=28), 1.8 (n=6), and 2 (n=6). For patients taking DOACs, 35/43 (81.4 %) and 8/43 (18.6 %) protocols advised timing of surgery based on renal function and absolute time from last dose respectively. Analysis of 10,197 patients from 78 hospitals showed fewer patients taking DOACs received surgery within 36 h of admission at hospitals with a dedicated protocol compared to those without (adjusted OR 0.73, 95% CI 0.54-0.99, p=0.040), while there were no differences among patients taking warfarin (adjusted OR 1.64, 95% CI 0.75-3.57, p=0.219). Conclusion(s): Around half of hospitals employed a dedicated anticoagulation management protocol for femoral fragility fracture patients, and substantial variation was observed in guidance between protocols. Dedicated protocols currently being used at hospitals were ineffective at improving the defined targets for time to surgery.

Link to full-text [open access - no password required]

Shropshire's military, NHS, and volunteer community collaborate to provide an innovative training course for medical registrars (2024)

Posted on by

Type of publication:
Conference abstract

Author(s):
*Eardley K.; *Mackintosh A.; *Wood G.;

Citation:
Future Healthcare Journal. Conference: The future of medicine. RCP annual conference. Regent's Park, London United Kingdom. 11(Supplement) (no pagination), 2024. Article Number: 100046. Date of Publication: April 2024.

Abstract:
Introduction: The position of Medical Registrar is one of the most important for the delivery of safe and effective emergency care in the acute hospital. It is also one of the most challenging physically and mentally. Health Education England West Midland's School of Medicine commissioned Shrewsbury & Telford Hospital NHS Trust (SATH) to deliver a 3-day residential course specifically designed to cover a wide range of competencies and clinical skills, but specifically to help equip the medical registrar with strategies to better manage the complexity, the cognitive load, and psychological stress of the role in a fun and interactive way. Material(s) and Method(s): The course was codesigned by SATH Volunteers, 202 Multi-role Medical Regiment (202MMR), NHS England OP COURAGE, SATH Clinical Simulation team, and RCP Chief Registrar. Feedback during the course meant that delegate's individual learning needs were identified and addressed in Course. Faculty provided feedback in person and a survey monkey was sent to the delegates on completion of the course. Results and discussion: The following course was delivered to 16 Internal Medicine Year 3 doctors. Deteriorating Patient Clinical Simulation Course: Delegates managed simulated clinical scenarios of deteriorating patients. Complexity called upon prioritisation, delegation, escalation, and communication skills. Simulated relatives were used calling on skills of breaking bad news, duty of candour, best interests' decision making, and providing compassionate end of life care. Human Factors Course: 202MMR Army Reservists and permanent staff delivered a course utilising the Centre of Army Leadership training packages. Using several engaging activities, the delegates gained a greater understanding of self and how their emotions, behaviours, and perceptions play an important role in their ability to be a safe and effective clinician, leader, and follower. Hospital Cardiac Arrest Clinical Simulation Course: All scenarios led onto cardiac arrest and included additional complexity requiring discussion with relatives including breaking bad news and making end of life decisions. Mental health session: This session provided a safe space for the delegates to talk about their experiences working in the NHS. Sustaining mental health and coping strategies and concepts were explored. Written feedback from the delegates was very positive and included: 'It was the best simulation course I have ever attended'. 'Role play by volunteers from the community was a unique experience which I have not observed in previous such training. This provided excellent opportunity to receive feedback on various aspects of our performance'. 'Focus on teamwork, leadership and followership is rarely spoken about in other training. Very dynamic and engaging'. 'Training in army barracks with command tasks correlating with leadership, teamwork and human factors. Interactive sessions, everyone was involved, valued, and listened'. 'The arrest scenarios were much truer to life than ALS courses eg relatives, debrief, bleed, thrombolysis'. 'Very useful feedback. Great to have the opportunity to try this before starting on the reg rota. Hugely appreciated thank you'. Conclusion(s): Utilising the skills and experiences of the NHS, military, and wider community significantly enhances the quality of clinical simulation and human factors training for the medical registrar.

Link to full-text [open access - no password required]

Patients' Preferences for Cytoreductive Treatments in Newly Diagnosed Metastatic Prostate Cancer: The IP5-MATTER Study (2024)

Posted on by

Type of publication:
Journal article

Author(s):
Connor, Martin J; Genie, Mesfin; Dudderidge, Tim; Wu, Hangjian; Sukumar, Johanna; Beresford, Mark; Bianchini, Diletta; Goh, Chee; Horan, Gail; Innominato, Pasquale; Khoo, Vincent; Klimowska-Nassar, Natalia; Madaan, Sanjeev; Mangar, Stephen; McCracken, Stuart; Ostler, Peter; Paisey, Sangeeta; Robinson, Angus; Rai, Bhavan; Sarwar, Naveed; *Srihari, Narayanan; Jayaprakash, Kamal Thippu; Varughese, Mohini; Winkler, Mathias; Ahmed, Hashim U; Watson, Verity.

Citation:
European Urology Oncology. 2024 Jul 06. [epub ahead of print]

Abstract:
BACKGROUND AND OBJECTIVE: Cytoreductive treatments for patients diagnosed with de novo synchronous metastatic hormone-sensitive prostate cancer (mHSPC) confer incremental survival benefits over systemic therapy, but these may lead to added toxicity and morbidity. Our objective was to determine patients' preferences for, and trade-offs between, additional cytoreductive prostate and metastasis-directed interventions. METHODS: A prospective multicentre discrete choice experiment trial was conducted at 30 hospitals in the UK between December 3, 2020 and January 25, 2023 (NCT04590976). The individuals were eligible for inclusion if they were diagnosed with de novo synchronous mHSPC within 4 mo of commencing androgen deprivation therapy and had performance status 0-2. A discrete choice experiment instrument was developed to elicit patients' preferences for cytoreductive prostate radiotherapy, prostatectomy, prostate ablation, and stereotactic ablative body radiotherapy to metastasis. Patients chose their preferred treatment based on seven attributes. An error-component conditional logit model was used to estimate the preferences for and trade-offs between treatment attributes. KEY FINDINGS AND LIMITATIONS: A total of 352 patients were enrolled, of whom 303 completed the study. The median age was 70 yr (interquartile range [IQR] 64-76) and prostate-specific antigen was 94 ng/ml (IQR 28-370). Metastatic stages were M1a 10.9% (33/303), M1b 79.9% (242/303), and M1c 7.6% (23/303). Patients preferred treatments with longer survival and progression-free periods. Patients were less likely to favour cytoreductive prostatectomy with systemic therapy (Coef. -0.448; [95% confidence interval {CI} -0.60 to -0.29]; p < 0.001), unless combined with metastasis-directed therapy. Cytoreductive prostate radiotherapy or ablation with systemic therapy, number of hospital visits, use of a "day-case" procedure, or addition of stereotactic ablative body radiotherapy did not impact treatment choice. Patients were willing to accept an additional cytoreductive treatment with 10 percentage point increases in the risk of urinary incontinence and fatigue to gain 3.4 mo (95% CI 2.8-4.3) and 2.7 mo (95% CI 2.3-3.1) of overall survival, respectively. CONCLUSIONS AND CLINICAL IMPLICATIONS: Patients are accepting of additional cytoreductive treatments for survival benefit in mHSPC, prioritising preservation of urinary function and avoidance of fatigue. PATIENT SUMMARY: We performed a large study to ascertain how patients diagnosed with advanced (metastatic) prostate cancer at their first diagnosis made decisions regarding additional available treatments for their prostate and cancer deposits (metastases). Treatments would not provide cure but may reduce cancer burden (cytoreduction), prolong life, and extend time without cancer progression. We reported that most patients were willing to accept additional treatments for survival benefits, in particular treatments that preserved urinary function and reduced fatigue.

Link to full-text [open access - no password required]

Automating incidence and prevalence analysis in open cohorts (2024)

Posted on by

Type of publication:
Journal article

Author(s):
Cockburn, Neil; Hammond, Ben; Gani, Illin; Cusworth, Samuel; Acharya, Aditya; Gokhale, Krishna; Thayakaran, Rasiah; Crowe, Francesca; Minhas, Sonica; *Smith, William Parry; Taylor, Beck; Nirantharakumar, Krishnarajah; Chandan, Joht Singh.

Citation:
BMC Medical Research Methodology. 24(1):144, 2024 Jul 04.

Abstract:
MOTIVATION: Data is increasingly used for improvement and research in public health, especially administrative data such as that collected in electronic health records. Patients enter and exit these typically open-cohort datasets non-uniformly; this can render simple questions about incidence and prevalence time-consuming and with unnecessary variation between analyses. We therefore developed methods to automate analysis of incidence and prevalence in open cohort datasets, to improve transparency, productivity and reproducibility of analyses. IMPLEMENTATION: We provide both a code-free set of rules for incidence and prevalence that can be applied to any open cohort, and a python Command Line Interface implementation of these rules requiring python 3.9 or later. GENERAL FEATURES: The Command Line Interface is used to calculate incidence and point prevalence time series from open cohort data. The ruleset can be used in developing other implementations or can be rearranged to form other analytical questions such as period prevalence. AVAILABILITY: The command line interface is freely available from https://github.com/THINKINGGroup/analogy_publication

Link to full-text [open access - no password required]

REPAIRS Delphi: A UK and Ireland Consensus Statement on the Management of Infected Arterial Pseudoaneurysms Secondary to Groin Injecting Drug Use (2024)

Posted on by

Type of publication:
Journal article

Author(s):
MacLeod C.S.; Nagy J.; Radley A.; Khan F.; Rae N.; Wilson M.S.J.; Suttie S.A.; Munro E.N.; Flett M.M.; Hussey K.; Wolf B.; W R.; Wallace D.; Vesey A.T.; McCaslin J.; Wong P.; Tenna A.; Badger S.; Harrison G.; Ghosh J.; Al-Khaffaf H.; Torella F.; McBride R.; Drinkwater S.; Antoniou G.A.; Bhasin N.; Pradhan A.; Smith G.; Coughlin P.; Brar R.; Peach G.; Kulkarni S.; Brooks M.; Wijesinghe L.; McCune K.; Hopper N.; Cowan A.; Hunter I.; Mittapalli D.; Garnham A.; *Jones S.; Rajagopalan S.; Tiwari A.; Imray C.; Atwal A.; Bahia S.; Jones K.G.; Handa A.; Bowbrick G.; Nordon I.; Button M.; Rudarakanchana N.; D'Souza R.; Tai N.; Moxey P.; Bicknell C.; Gibbs R.; Zayed H.; Saratzis A.; Kannan R.; Batchelder A.; Chong P.L.; Rowlands T.; Hildebrand D.; Thapar A.; Chaudhuri A.; Howard A.; Metcalfe M.; Al-Jundi W.; Sayer G.; Lewis D.; Sohrabi S.; Woolgar J.; Fligelstone L.; Davies H.; Hill S.; Fulton G.; Moneley D.; McDonnell C.; Martin Z.; Dowdall J.; Tierney S.; Walsh S.; Medani M.; Gosi G.

Citation:
European Journal of Vascular and Endovascular Surgery. (no pagination), 2024 [epub ahead of print]

Abstract:
Objective: Consensus guidelines on the optimal management of infected arterial pseudoaneurysms secondary to groin injecting drug use are lacking. This pathology is a problem in the UK and globally, yet operative management options remain contentious. This study was designed to establish consensus to promote better management of these patients, drawing on the expert experience of those in a location with a high prevalence of illicit drug use. Method(s): A three round modified Delphi was undertaken, systematically surveying consultant vascular surgeons in the UK and Ireland using an online platform. Seventy five vascular surgery units were invited to participate, with one consultant providing the unit consensus practice. Round one responses were thematically analysed to generate statements for round two. These statements were evaluated by participants using a five point Likert scale. Consensus was achieved at a threshold of 70% or more agreement or disagreement. Those statements not reaching consensus were assessed and modified for round three. The results of the Delphi process constituted the consensus statement. Result(s): Round one received 64 (86%) responses, round two 59 (79%) responses, and round three 62 (83%) responses; 73 (97%) of 75 units contributed. Round two comprised 150 statements and round three 24 statements. Ninety one statements achieved consensus agreement and 15 consensus disagreement. The Delphi statements covered sequential management of these patients from diagnosis and imaging, antibiotics and microbiology, surgical approach, wound management, follow up, and additional considerations. Pre-operative imaging achieved consensus agreement (97%), with computerised tomography angiography being the modality of choice (97%). Ligation and debridement without arterial reconstruction was the preferred approach at initial surgical intervention (89%). Multidisciplinary management, ensuring holistic care and access to substance use services, also gained consensus agreement. Conclusion(s): This comprehensive consensus statement provides a strong insight into the standard of care for these patients.

Link to full-text [open access - no password required]

The diagnosis and management of systemic autoimmune rheumatic disease-related interstitial lung disease: British Society for Rheumatology guideline scope (2024)

Posted on by

Type of publication:
Journal article

Author(s):
Hannah, Jennifer; Rodziewicz, Mia; Mehta, Puja; Heenan, Kerri-Marie; Ball, Elizabeth; Barratt, Shaney; Carty, Sara; Conway, Richard; Cotton, Caroline V; Cox, Sarah; Crawshaw, Anjali; Dawson, Julie; Desai, Sujal; Fahim, Ahmed; Fielding, Carol; *Garton, Mark; George, Peter; Gunawardena, Harsha; Kelly, Clive; Khan, Fasihul; Koduri, Gouri; Morris, Helen; Naqvi, Marium; Perry, Elizabeth; Riddell, Claire; Sieiro Santos, Cristiana; Spencer, Lisa G; Chaudhuri, Nazia; Nisar, Muhammad K.

Citation:
Rheumatology Advances in Practice. 8(2):rkae056, 2024.

Abstract:
Interstitial lung disease (ILD) is a significant complication of many systemic autoimmune rheumatic diseases (SARDs), although the clinical presentation, severity and outlook may vary widely between individuals. Despite the prevalence, there are no specific guidelines addressing the issue of screening, diagnosis and management of ILD across this diverse group. Guidelines from the ACR and EULAR are expected, but there is a need for UK-specific guidelines that consider the framework of the UK National Health Service, local licensing and funding strategies. This article outlines the intended scope for the British Society for Rheumatology guideline on the diagnosis and management of SARD-ILD developed by the guideline working group. It specifically identifies the SARDs for consideration, alongside the overarching principles for which systematic review will be conducted. Expert consensus will be produced based on the most up-to-date available evidence for inclusion within the final guideline. Key issues to be addressed include recommendations for screening of ILD, identifying the methodology and frequency of monitoring and pharmacological and non-pharmacological management. The guideline will be developed according to methods and processes outlined in Creating Clinical Guidelines: British Society for Rheumatology Protocol version 5.1.

Link to full-text [open access - no password required]

Persistent sweet taste dysgeusia diagnosed with probable SIADH: Unmasking underlying lung cancer in a high-risk individual: A case report (2024)

Posted on by

Type of publication:
Journal article

Author(s):
*Praveenkumar Katarki, *Lyudmyla Nod, *Nawaid Ahmad

Citation:
Clinical Medicine 2024. Volume 24, Supplement, April 2024

Abstract:
Introduction: The timely identification of lung cancer is critical but difficult due to its broad and often nonspecific symptoms. This case report highlights the importance of taking into consideration unusual manifestations, especially in persons at high risk, and emphasises the necessity of a thorough diagnostic approach. Case presentation: A 66-year-old female referred from the general practitioner (GP)to the same day emergency care (SDEC) with persistent sweet taste dysgeusia, headache and hyponatraemia (118). Notably, her chest X-ray was unremarkable (image 1) despite a 30-pack-year smoking history. Initial suspicion was on drug-induced syndrome of inappropriate antidiuretic hormone secretion (SIADH) potentially due to her long-term use of gabapentin (for 25 years), as reported in a retrospective study conducted in Sweden.1 However, an inadequate response to treatment prompted further investigation, CT thorax (image 2) revealing primary lung malignancy with liver metastases. A histological evidence is awaited, the radiological diagnosis of the lung cancer was considered after discussion at Lung cancer at the multidisciplinary team. Discussion: This case further strengthens the growing body of evidence suggesting sweet taste dysgeusia as a rare paraneoplastic symptom of small cell lung cancer (SCLC), as documented in previous studies.2–5 The potential mechanisms underlying this phenomenon remain unclear, but possibilities include ectopic antidiuretic hormone (ADH) production4, tumour-derived substances affecting taste pathways5 or metabolic disturbances associated with the malignancy itself.4,5 This case underscores the critical need for heightened suspicion for malignancy, especially in high-risk individuals like smokers, even when presenting with seemingly common diagnoses like SIADH. Additionally, it highlights the limitations of solely relying on initial symptoms and investigations. Notably, the patient had an unremarkable chest X-ray (image 1) despite a significant 40-pack-year smoking history, emphasising the importance of employing a comprehensive diagnostic approach. This approach should encompass a detailed medical history and risk factor evaluation, thorough physical examination for potential malignancy signs, targeted laboratory investigations including electrolytes, renal function, and tumour markers, and appropriate imaging studies based on clinical suspicion and initial findings (chest X-ray, CT scan). While this case showcases the potential of sweet taste dysgeusia as a paraneoplastic sign, several limitations must be acknowledged. First, this symptom remains rare and its specificity for SCLC is uncertain; Second, potential selection bias towards atypical presentations could overestimate its prevalence.7 Finally, confounding factors like hyponatraemia itself can affect taste perception.4. Conclusion: This case contributes to the growing evidence suggesting sweet taste dysgeusia could be an atypical early warning sign of lung cancer, particularly in high-risk individuals. While limitations exist and further research is warranted, this association necessitates further investigation due to its potential implications for earlier detection and improved patient outcomes. Recognising limitations, advocating for further research, and emphasising potential clinical impact contribute to ongoing efforts in improving lung cancer diagnosis and management.

Link to full-text [open access - no password required]

Statins As Anti-Hypertensive Therapy: A Systematic Review and Meta-Analysis (2024)

Posted on by

Type of publication:
Systematic Review

Author(s):
Khan, Zahid; Gul, Amresh; Mlawa, Gideon; Bhattacharjee, Priyadarshini; Muhammad, Syed Aun; Carpio, Jonard; *Yera, Hassan; Wahinya, Maureen; Kazeza, Axel P; Amin, Mehul S; Gupta, Animesh.

Citation:
Cureus. 16(4):e57825, 2024 Apr.

Abstract:
Hypertension is the most prevalent condition in clinical practice. Hypertension, diabetes, and hypercholesterolaemia are major contributing factors to cardiovascular diseases. They commonly coexist in a single patient. Statins have been used as prominent medicines for the reduction of cardiovascular events. Statins have been shown to reduce blood pressure in patients with hypertension and have lipid-lowering properties in recent articles. Statins reduce blood pressure because of their impact on endothelial function, their interactions with the renin-angiotensin system, and their influence on major artery compliance. This meta-analysis aimed to ascertain the effectiveness and efficacy of statins for managing hypertension in patients with hypertension. Systematic searches were conducted on PubMed, Science Direct, Embase, Cochrane Library, and Google Scholar. Randomized controlled trials, systematic trials, and cohort studies were retrieved using keywords on statins and their use in patients with hypertension. Exclusion criteria included studies that were not in the English language, studies that did not include patients on statins with hypertension, studies that did not provide enough information, technical reports, opinions, or editorials, and studies involving patients < 18 years old. The inclusion criteria were randomized controlled trials, meta-analyses, adult patients aged > 18 years old, and studies that were freely available or through institutional login. This meta-analysis scrutinized 9361 randomized controlled trials, clinical trials, meta-analyses, and systematic reviews, of which 32 articles including 25 randomized controlled trials and seven meta-analyses were included in the final analysis. This meta-analysis of the role of statins in hypertensive patients aimed to determine the outcome of hypertension control along with antihypertensive medication. Our study showed that statins are useful in reducing both systolic and diastolic blood pressure. We used a heterogeneous model for analysis due to variations in the study characteristics. The I2 value was 0.33 (0.76, 0.10) for systolic blood pressure and 0/88 (0.86, 0.90) for diastolic blood pressure. The I2 value for the seven meta-analyses included in the study was 1.79 (2.88, 0.69).

Link to full-text [open access - no password required]

Comparison of the Latarjet Procedure With the Modified Putti-Platt Surgery for Recurrent Anterior Shoulder Dislocation With Respect to Functional Outcome (2024)

Posted on by

Type of publication:
Journal article

Author(s):
Anjum, Ihtisham; Ullah, Ubaid; *Fazli Maula, Aimen; Haroon, Hamza; Ahmad, Yaseen; Hassan, Rao E; Shahid, Kashan; Hussain, Saddam; Haider, Waseem; Ullah, Rizwan

Citation:
Cureus. 16(3):e57270, 2024 Mar.

Abstract:
Introduction Shoulder dislocation is the most common injury encountered in orthopedic outpatient department. The choice of procedure depends on the expertise of surgeons. The objective of this study was to compare the Latarjet procedure with the modified Putti-Platt surgery for recurrent anterior shoulder dislocation in terms of functional outcomes. Materials and methods A quasi-experimental study evaluated 60 patients with recurrent anterior shoulder instability. Patients were assigned to either Latarjet or modified Putti-Platt surgery. Functional outcomes were assessed at six months using the Constant-Murley shoulder score. Results This study encompassed 60 patients (mean age: 23.93+/-5.88 years) undergoing shoulder procedures. Functional outcomes exhibited a majority of 55% excellent, 35% good, 6.7% fair, and 3.3% poor outcomes. No significant differences in functional outcomes were found between the procedures. Conclusion Both procedures may be viable options for recurrent shoulder instability. The choice may depend on patient factors and surgeon preference. Further research is needed to refine techniques and identify ideal candidates.

Link to full-text [open access - no password required]

Frequency of CLAR and JAK2 mutations in Sudanese chronic myeloid leukemia patients with Philadelphia-positive disease (2024)

Posted on by

Type of publication:
Journal article

Author(s):
Yasin E.B.; *Yasin A.

Citation:
Asian Journal of Pharmaceutical and Clinical Research. 16(8) (pp 133-137), 2023. Date of Publication: August 2023.

Abstract:
Objective: It is well-established that myeloproliferative diseases coexist with CLAR and JAK2. In Ph+ chronic myeloid leukemia (CML), only a few case reports indicate the existence of CLAR, JAK2V617F, and JAK2 exon 12 mutations. Method(s): This study examined CALR and JAK2 mutation profiles in Sudanese Chronic Myeloid Leukemia patients with Philadelphia-positive patients. Blood samples were collected from 100 patients with Ph+ CML chromosomes. Results for the JAK2V617F mutation were confirmed using the TaqMan Mutation Detection Assay, and the four common mutations on exon 12 and CLAR mutations were confirmed using allele-specific PCR (AS-PCR) and Sanger sequencing. Result(s): CML patients with CALR frameshift mutations were detected in two patients (2%), patients with JAK2 exon 12 mutations were found in two patients (2%), and patients with JAK2V617F mutations made up 4 (4%) of the total CML patients. No significant relationships existed between mutations and age, WBC, RBC, Hb, HCT, or platelet parameters. Patients with CLAR, JAK2 exon 12, and JAK2V617F mutations have normal leukocyte counts and lower values compared to triple-negative Ph+ CML, but these differences are not statistically significant (p values for each 0.084, 0.173, and 0.072). Conclusion(s): It is conceivable for Ph+ CML and all mutations to coexist.

Link to full-text [open access - no password required]